Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Phosphorus or phosphorus compound
Reexamination Certificate
2005-07-26
2005-07-26
Levy, Neil S. (Department: 1616)
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Phosphorus or phosphorus compound
C424S604000
Reexamination Certificate
active
06921544
ABSTRACT:
A stable, phase-pure magnesium-substituted crystalline hydroxyapatite containing from about 2.0 to about 29 wt % magnesium, wherein at least 75 wt % of the magnesium content is substituted for calcium ions in the hydroxyapatite lattice structure.
REFERENCES:
patent: 4097935 (1978-07-01), Jarcho
patent: 5830480 (1998-11-01), Ducheyne et al.
patent: 6027742 (2000-02-01), Lee et al.
patent: 97/17285 (1997-05-01), None
patent: 99/32400 (1999-07-01), None
patent: WO00/03747 (2000-01-01), None
Yaoukawa et al. Preparation—Mg-Cahae J. Mater. Chem. 6(8) p. 1401-1405 '96.
Bertoni et al., “Nanocrystals of magnesium and fluoride substituted hydroxyapatite,” J. Inorg. Biochem., 72 (1):29-35 (1998).
Bigi et al., “Magnesium Influence on Hydroxyapatite Crystallization,”J. Inorg. Biochem., 49, 69-78 (1993).
Riman Richard E.
Shuk Pavel
Suchanek Wojciech
TenHuisen Kevor S.
Rutgers The State University
Synnestvedt Lechner & Woodbridge LLP
LandOfFree
Magnesium-substituted hydroxyapatites does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Magnesium-substituted hydroxyapatites, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Magnesium-substituted hydroxyapatites will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3398836